BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

17 articles for WM Kazmierski

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound.EBI
Glaxosmithkline
Novel 4,4-disubstituted piperidine-based C-C chemokine receptor-5 inhibitors with high potency against human immunodeficiency virus-1 and an improved human ether-a-go-go related gene (hERG) profile.EBI
Glaxosmithkline
Discovery of bioavailable 4,4-disubstituted piperidines as potent ligands of the chemokine receptor 5 and inhibitors of the human immunodeficiency virus-1.EBI
Glaxosmithkline
Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.EBI
Ono Pharmaceutical
Discovery of N-benzyl-N'-(4-pipyridinyl)urea CCR5 antagonists as anti-HIV-1 agents (II): modification of the acyl portion.EBI
Glaxosmithkline
Discovery of N-benzyl-N'-(4-pipyridinyl)urea CCR5 antagonists as anti-HIV-1 agents (I): optimization of the amine portion.EBI
Glaxosmithkline
 
A new approach to enhance bioavailability of biologically active peptides: conjugation of a δ opioid agonist to β-cyclodextrinEBI
TBA
[2-(4-Phenyl-4-piperidinyl)ethyl]amine based CCR5 antagonists: derivatizations at the N-terminal of the piperidine ring.EBI
Glaxosmithkline
The Discovery of Conformationally Constrained Bicyclic Peptidomimetics as Potent Hepatitis C NS5A Inhibitors.EBI
Glaxosmithkline
GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage.EBI
Glaxosmithkline
DNA-Encoded Library Technology-Based Discovery, Lead Optimization, and Prodrug Strategy toward Structurally Unique Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors.EBI
Glaxosmithkline
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety.EBI
Glaxo Wellcome Research and Development
Selective glycosidase inhibitors and uses thereofBDB
Alectos Therapeutics
BTK InhibitorsBDB
Merck Sharp & Dohme
Macrocyclic compounds as Trk kinase inhibitorsBDB
Array Biopharma
Substituted aza-bicyclic imidazole derivatives useful TRPM8 receptor modulatorsBDB
Janssen Pharmaceutica
Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor.BDB
University of Auckland